SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-062468
Filing Date
2023-11-13
Accepted
2023-11-13 08:03:08
Documents
14
Period of Report
2023-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rapt-20231113.htm   iXBRL 8-K 47303
2 EX-99.1 rapt-ex99_1.htm EX-99.1 215008
3 GRAPHIC img152904466_0.jpg GRAPHIC 3854
  Complete submission text file 0000950170-23-062468.txt   398995

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rapt-20231113.xsd EX-101.SCH 2457
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rapt-20231113_lab.xml EX-101.LAB 14018
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rapt-20231113_pre.xml EX-101.PRE 10279
8 EXTRACTED XBRL INSTANCE DOCUMENT rapt-20231113_htm.xml XML 4930
Mailing Address 561 ECCLES AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 561 ECCLES AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 489-9000
RAPT Therapeutics, Inc. (Filer) CIK: 0001673772 (see all company filings)

IRS No.: 473313701 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38997 | Film No.: 231395256
SIC: 2834 Pharmaceutical Preparations